- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01715350
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease (ADD)
A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease: Double-Blind, Randomized Between Placebo Control Group and Dose Groups, Parallel-Design, Multicenter Study
Study Overview
Detailed Description
Period of study
-48 months from the date of KFDA approval of the protocol
Study subjects
-Patients with mild to moderate Alzheimer's disease
Study objectives
Primary objective
- To compare the efficacy of 2 doses of PM012 Tablet and placebo based on cognitive effect assessed by ADAS-cog at Week 12 post-dose
Secondary objectives
- To compare the efficacy of 2 doses of PM012 Tablet and placebo based on cognitive effect assessed by ADAS-cog at Week 8 post-dose
- To compare the efficacy of 2 doses of PM012 Tablet and placebo based on overall functional effect assessed by CDR at Weeks 8 and 12 post-dose
- To compare the efficacy of 2 doses of PM012 Tablet and placebo based on activities of daily living assessed by K-IADL at Weeks 8 and 12 post-dose
- To compare the efficacy of 2 doses of PM012 Tablet and placebo based on behavioral changes assessed by NPI at Weeks 8 and 12 post-dose
- To compare the efficacy of 2 doses of PM012 Tablet and placebo based on cognitive effect assessed by K-MMSE at Weeks 8 and 12 post-dose
- To compare the efficacy of 2 doses of PM012 Tablet and placebo based on improvement on VAS assessed by Senile Dementia Pattern Identification Diagnosis System at Weeks 8 and 12 post-dose
Study drug / Comparator
-650-mg PM012 Tablet by PuriMED Co., Ltd. / Placebo
Dosage/ Administration and Method of administration
Placebo group
- Morning:Placebo 2T, Evening:Placebo 2T
Dose group 1
- Morning:Placebo 1T+Study drug 1T, Evening:Placebo 1T+Study drug 1T
Dose group 2
- Morning:Study drug 2T, Evening:Study drug 2T
- Study drug is 650-mg PM012 tablet
- The drug will be taken with water within 30 minutes after breakfast and supper.
- Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water.
Treatment duration
-12 weeks
Number of subjects
placebo group
- Efficacy population:42, Drop-out(20%)included:53
Dose group 1
- Efficacy population:42, Drop-out(20%)included:53
Dose group 2
- Efficacy population:42, Drop-out(20%)included:53
Total
- Efficacy population:126, Drop-out(20%)included:159
Study method
- This study is designed to be a multicenter, randomized, double-blind, parallel placebo group and 2 dose groups, phase 2 clinical study in patients with dementia of Alzheimer's type aged ≥ 50 and ≤ 85 years.
- Once a subject voluntarily provides the written consent to participate in the study, he/she will be randomized only if meeting the inclusion criteria and exclusion criteria through screening test. Randomized subjects will receive the study drug or the placebo for 12 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Dongdaemun-gu
-
Seoul, Dongdaemun-gu, Korea, Republic of, 130-872
- Kyung Hee University Oriental Medicine Hospital
-
-
Ilsandong-gu
-
Goyang, Ilsandong-gu, Korea, Republic of, 410-719
- National Health Insurance Corporation Ilsan Hospital
-
-
Paldal-gu
-
Suwon, Paldal-gu, Korea, Republic of, 442-72
- The Catholic University of Korea, St. Vincent's Hospital
-
-
Seocho-gu
-
Seoul, Seocho-gu, Korea, Republic of, 137-701
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1)Male and female patients aged ≥ 50 and ≤ 85 years
- 2)Clinically diagnosed with probable Alzheimer's disease based on DSM-IV and NINCDS-ADRDA criteria
- 3)K-MMSE score of 12~26 at screening visit
- 4)For females: 2 years of confirmed menopause or surgical sterilization.
- 5)Able to walk (including the use of aids)
- 6)Able to perform procedures for cognitive and other tests
- 7)Residing with a life-long guardian willing to accompany the subject's on all visits, oversee his/her compliance with the procedures specified in the protocol and the study drug, and report his/her condition.
- 8)Having signed him/herself or his/her legally acceptable representative having signed the written informed consent form
Exclusion Criteria:
- 1)Possible, probable, or definite vascular dementia by NINDS-AIREN criteria
- 2)History and/or evidence (result of CT or MRI performed within the past 12 months or at screening) of other CNS disease (cerebrovascular disease, structural or developmental anomaly, epilepsy, contagious, degenerative or infectious/demyelinating CNS condition) as a cause of dementia
- 3)Delusion, delirium, epilepsy and other neurological pathology on neurological examination
- 4)Abnormal test result on vitamin B12, syphilis serology, and thyroid stimulating hormone (TSH) tests that are thought to contribute to the subject's dementia severity or be a cause of dementia
- 5)History of significant psychiatric disease such as schizophrenia or bipolar affective disorder that may interfere with the participation in this study in the opinion of the investigator, or current depression (GDS ≥ 18)
- 6)Past history of known or suspected seizures including febrile convulsion, unexplained recent unconsciousness or past history of significant head trauma with unconsciousness.
- 7)Gastrointestinal, endocrine and cardiovascular disease not controlled by diet or pharmacologic therapy
- 8)Cardiac disease such as myocardial infarction or valvular disease of heart, arrhythmia within 3 months of the study start
- 9)Diabetes mellitus not controlled by hypoglycemic agent or insulin-dependent diabetes mellitus
- 10)Past history of alcohol or other drug abuse
- 11)Having taken acetylcholinesterase inhibitor or memantine within the past 3 months
- 12)Hypertension with systolic blood pressure of > 165 mmHg or diastolic blood pressure of > 96 mmHg
- 13)Severe renal impairment (serum creatinine ≥ 1.7 mg/dl)
- 14)Severe hepatic impairment (ALT, AST, or bilirubin ≥ 2.0 x upper limit of normal)
- 15)Is taking or expected to take disallowed concomitant medication
- 16)History of clinically significant drug hypersensitivity
- 17)Is ineligible to participate in this study in the judgment of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo group
• Drug : Placebo 2 tablet The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water. |
Other Names:
|
EXPERIMENTAL: Dose group 1
The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water. |
Other Names:
Other Names:
|
EXPERIMENTAL: Dose group 2
The drug will be taken with water within 30 minutes after breakfast and supper. Even if no meal is taken, dosing will not be omitted and the drug should be taken with enough amount of water. |
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ADAS-cog
Time Frame: Week 12 post-dose
|
* To compare the efficacy of 2 doses of PM012 Tablet and placebo based on cognitive effect assessed by ADAS-cog at Week 12 post-dose
|
Week 12 post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ADAS-cog
Time Frame: Weeks 8 post-dose
|
* To compare the efficacy of 2 doses of PM012 Tablet and placebo based on cognitive effect assessed by ADAS-cog at Week 8 post-dose
|
Weeks 8 post-dose
|
CDR
Time Frame: Weeks 8 and 12 post-dose
|
* To compare the efficacy of 2 doses of PM012 Tablet and placebo based on overall functional effect assessed by CDR at Weeks 8 and 12 post-dose
|
Weeks 8 and 12 post-dose
|
K-IADL
Time Frame: Weeks 8 and 12 post-dose
|
* To compare the efficacy of 2 doses of PM012 Tablet and placebo based on activities of daily living assessed by K-IADL at Weeks 8 and 12 post-dose
|
Weeks 8 and 12 post-dose
|
NPI
Time Frame: Weeks 8 and 12 post-dose
|
* To compare the efficacy of 2 doses of PM012 Tablet and placebo based on behavioral changes assessed by NPI at Weeks 8 and 12 post-dose
|
Weeks 8 and 12 post-dose
|
K-MMSE
Time Frame: Weeks 8 and 12 post-dose
|
* To compare the efficacy of 2 doses of PM012 Tablet and placebo based on cognitive effect assessed by K-MMSE at Weeks 8 and 12 post-dose
|
Weeks 8 and 12 post-dose
|
VAS
Time Frame: at Weeks 8 and 12 post-dose
|
* To compare the efficacy of 2 doses of PM012 Tablet and placebo based on improvement on VAS assessed by Senile Dementia Pattern Identification Diagnosis System at Weeks 8 and 12 post-dose
|
at Weeks 8 and 12 post-dose
|
AE
Time Frame: while the subject is receiving the treatment
|
* To compare the safety based on treatment-emergent adverse events, laboratory tests (hematology/blood chemistry, urinalysis), physical examination, vital signs
|
while the subject is receiving the treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Seoung-Hun Cho, M.D., Kyung Hee University Oriental Medicine Hospital
- Principal Investigator: Chang-Uk Lee, M.D., The Catholic University of Korea
- Principal Investigator: Hyun-Kook Lim, M.D., Saint Vincent's Hospital, Korea
- Principal Investigator: Jun-Hong Lee, M.D., National Health Insurance Service Ilsan Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PM012-P2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States